Crossmark

Pathologic response as an early endpoint for survival following neoadjuvant androgen deprivation therapy plus abiraterone acetate for metastatic prostate cancer

Crossref DOI link: https://doi.org/10.1186/s40001-025-02521-7

Published Online: 2025-04-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhou, Kaichen

Lu, Haosen

Wei, Fukun

Wang, Jie

Song, Zhen

Mao, Lijun
License Information

Text and Data Mining valid from 2025-04-04

Version of Record valid from 2025-04-04
More Information

Article History

Received: 17 November 2024

Accepted: 27 March 2025

First Online: 4 April 2025

Declarations

:

: The institutional review board authorized this study (approval No. XYFY2021-KL325-01). All of the patients provided informed consent.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below